Introduction
Dexrazoxane (Zinecard, Cardioxane, ADR-529, ICRF-187), 1 , reduces the cardiomyopathic effects of the antitumor antibiotic doxorubicin (Adriamycin), effective!y raising the lifetime maximum dose of doxorubicin. The cardiotoxicity of doxorubicin =s believed to be due to an iron-mediated production of reactive hydroxyl radicals, HO..3which have been associated with lipid peroxidation and protein and nucleic acid cleavage.
It is generally thought that the nonpolar dexrazoxane hydrolyzes intracellularly to 2 (ADR-925), a polar bisamide/bisacid analog of the metal ion chelator EDTA (3), reducing the availability of iron to doxorubicin and, hence, the production of hydroxyl radicals." In addition to the enantiomerically-pure dexrazoxane both its racemate razoxane (ICRF-159) and its desmethyl form (ICRF-154, EDTA-diimide, ,), are alone effective against murine tumor models. 4, 5 Razoxane was previously used to treat breast masses as well as psoriasis, but treatment with EDTA-diimide derivatives led to generalized carcinogenesis as therapy-related leukemia. 5'6 Like doxorubicin, razoxane is thought to target topoisomerase II (although by a different mechanism); however it was shown to hydrolyze intracellularly and was initially thought to be involved in metal ion chelation. Dexrazoxane is prescribed at lower doses in cardioprotection (500-600 mg/m2) than razoxane was as an antineoplastic (500-1500 mg/m2), but an important therapeutic issue is the limit of the ability of dexrazoxane to reduce doxorubicin-related toxicity, especially since razoxane was shown to act synergistically with doxorubicin as an antitumor agent. ' Indeed, Imondi et al. recently showed that proportionally greater doses of dexrazoxane are poorer inhibitors of cardiomyopathy at increasing doses of doxorubicin in animal models. 3 Hasinoff and Winterbourn have illustrated the ability of the hydrolysis product of razoxane , the racemate of ADR-925) to remove iron(Ill) from doxorubicin, and there is recent evidence that the iron-bound hydrolysis product of dexrazoxane is involved in hydroxyl-radical production. 4 DNA was cleaved by the Fe-EDTA-bisamide under Fenton conditions. At 100 pM, Fe-EDTA and Fe-EDTA-bisamide both cleaved the plasmid with greater efficiency than ferrous chloride (Table I) . At 10 #M, Fe-EDTA and Fe-EDTA-bisamide cleaved the DNA with approximately equal efficiency. However, Fe-EDTA cleaved the DNA more efficiently than Fe-EDTA-bisamide at both #M and 100 #M; this is especially unusual, since Fe-EDTAbisamide cleaved the DNA less efficiently at 100 l.tM (the higher concentration) than at 10 l.tM (Figure 1 ). Fe-ADR-925 (the iron-bound hydrolysis product of dexrazoxane) was also able to cleave DNA (Table II) The cleavage of DNA in the presence of ferrous chloride, Fe-EDTA and Fe-EDTA-bisamide (all at 10 #M) was inhibited by the radical scavenger thiourea (Table III) . At 5 mM thiourea, cleavage by ferrous chloride was almost entirely retarded, and cleavage by Fe-EDTA and Fe-EDTA-bisamide was reduced by half. Thiourea at 500 mM approximately completely prevented DNA cleavage (Figure 2 ).
Discussion
Razoxane, like other EDTA-diimide drugs (ICRF-154, dexrazoxane), is an antineoplastic, and this is probably due at least in part to inhibition of topoisomerase II. 5, 7 At lower doses, dexrazoxane, which is simply enantiomerically-pure razoxane, ameliorates the cardiotoxicity of doxorubicin therapy. However, such diimides are also carcinogenic, and both razoxane and dexrazoxane hydrolyze in vivo to metal-ion chelators that can produce Our lab has observed that high (preparative) concentrations of ferrous chloride and EDTA-bisamide result in an initially yellow solution that turns brown over time at relatively low pH. UV studies have indicated that this is a secondary base-catalyzed reaction after complex formation, and spectrophotometric similarities between this reaction and formation of the Fe-EDTA p-.oxo dimer suggest that such iLt-OXO dimerization may be occurring with Fe-EDTA...bisamide and Fe-ADR-925, as well ( Figure 3 ). Dimer formation for Fe-ADR-925 begins at higher basicity (pH~6)than for Fe-EDTA-bisamide (pH~5), perhaps because the methyl substituent on ADR-925 decreases the Lewis acidity of the iron in that complex. 5 Attempts to determine dimerization constants by spectrophotometric titrations have been hindered by precipitation problems under the conditions needed for this analysis. e Further attempts to obtain these constants kinetically have likewise proven difficult due to mechanistic complexities. More work is needed, and a full analysis of this system is ongoing in our lab. The higher pHs at which Fe-EDTA and Fe-ADR-925 undergo monomer-dimer equilibrium, however, correspond well with the differential concentration/cleavage profiles of Fe-EDTAbisamide, Fe-ADR-925 and Fe-EDTA. The inhibition of these DNA scission reactions by thiourea probably does not rule out either additional oxidizing species or modes of inhibition in addition to radical scavenging. In particular, thiourea might react with other electrondeficient species that could cleave DNA, and might also be binding to the metal center.
The former is particularly worth further investigation since the ferryl species [FeV=O(EDTA bisamide)] would be neutral as opposed to [Fe=O(EDTA)] -, which would be negative (same as the DNA backbone).
We would like to suggest that the ability of the iron-bound hydrolysis products of dexrazoxane and ICRF-154 to cleave DNA might account for the carcinogenic nature of the diimide drugs, and this implies a therapeutic limit to dexrazoxane. Furthermore, it does not seem clear at this time that such a route might not also be a substantial contributor to the in vivo mechanism of the antitumor activity by razoxane. Most importantly, the production of the very same oxidizing species, HO, thatis taken to be responsible for doxorubicin toxicity at least suggests that there may be a maximum dose for doxorubicin/dexrazoxane combination.
Moreover, the relative ease with which Fe-EDTA-bisamide and Fe-ADR-925 form dimers at near physiological pH suggests that the local concentration in vivo may be important to the iron-bound drug's overall reactivity. This calls for further chemical and, especially, clinical study.
